Hr Positive | List of Frontiers open access articles

Review

Published on 22 Jan 2026

Optimizing second-line endocrine-based treatment in HR positive HER2 negative metastatic breast cancer: a comprehensive expert statement from the Gulf Cooperation Council Region

in Breast Cancer

Ahmed Alshehri
Abdullah Khalaf Altwairgi
Abdulwahab AlTourah
Ahmed Alwbari
Aref Chehal
Francois Calaud
Hashem Al-Hashem
Husam Marashi
Sherif Elsamany
Syed Hammad Tirmazy

Frontiers in Oncology

doi 10.3389/fonc.2025.1706670

1,462 views

Review

Published on 10 Aug 2018

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

in Women's Cancer

Tarah J. Ballinger
Jason B. Meier
Valerie M. Jansen

Frontiers in Oncology

doi 10.3389/fonc.2018.00308

14,994 views
72 citations

Case Report

Published on 22 Feb 2021

Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression

in Cancer Immunity and Immunotherapy

Dingyong Wu
Shu Tang
Rong Ye
Dongmei Li
Dejian Gu
Rongrong Chen
Huan Zhang
Jianguo Sun
Zhengtang Chen

Frontiers in Immunology

doi 10.3389/fimmu.2021.610149

7,271 views
11 citations

Review

Published on 12 Jul 2021

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

in Breast Cancer

Mridula A. George
Sadaf Qureshi
Coral Omene
Deborah L. Toppmeyer
Shridar Ganesan

Frontiers in Oncology

doi 10.3389/fonc.2021.693104

48,097 views
137 citations

Original Research

Published on 05 Mar 2025

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy

in Breast Cancer

Yingbo Shao
Huijuan Guan
Zhifen Luo
Yang Yu
Yaning He
Qi Chen
Chaojun Liu
Fangyuan Zhu
Hui Liu

Frontiers in Oncology

doi 10.3389/fonc.2025.1459444

1,947 views

Original Research

Published on 28 Jul 2022

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer

in Molecular and Cellular Oncology

Yingbo Shao
Zhifen Luo
Yang Yu
Yaning He
Chaojun Liu
Qi Chen
Fangyuan Zhu
Bing Nie
Hui Liu

Frontiers in Oncology

doi 10.3389/fonc.2022.939343

3,187 views
13 citations

Articles

Optimizing second-line endocrine-based treatment in HR positive HER2 negative metastatic breast cancer: a comprehensive expert statement from the Gulf Cooperation Council Region

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer